Phase III Confirmatory Trial to Confirm the Anti-anginal Effect of Dantonic (T89) in Patients With Chronic Stable Angina.
Phase of Trial: Phase III
Latest Information Update: 14 Mar 2017
At a glance
- Drugs T 89 (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Acronyms CAESA
- Sponsors Tasly Pharmaceuticals, Inc.
- 07 Mar 2017 Status changed from active, no longer recruiting to completed.
- 04 Jul 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2016.
- 04 Jul 2016 Status changed from recruiting to active, no longer recruiting.